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Abstract. 
 
To understand the mechanism by which 
human immunodeficiency virus type 1 (HIV) capsids 
are formed, we have reconstituted the assembly of im-
mature HIV capsids de novo in a cell-free system. 
Capsid authenticity is established by multiple biochem-
ical and morphologic criteria. Known features of the as-
sembly process are closely reproduced, indicating the 
fidelity of the cell-free reaction. Assembly is separated 
into co- and posttranslational phases, and three inde-
pendent posttranslational requirements are demon-
strated: (
 
a
 
) ATP, (
 
b
 
) a detergent-sensitive host factor, 
and (
 
c
 
) a detergent-insensitive host subcellular fraction 
that can be depleted and reconstituted. Assembly ap-
pears to proceed by way of multiple intermediates 
whose conversion to completed capsids can be blocked 
by either ATP depletion or treatment with nondenatur-
ing detergent. Specific subsets of these intermediates 
accumulate upon expression of various assembly-defec-
tive Gag mutants in the cell-free system, suggesting that 
each mutant is blocked at a particular step in assembly. 
Furthermore, the accumulation of complexes of similar 
sizes in cells expressing the corresponding mutants sug-
gests that comparable intermediates may exist in vivo. 
From these data, we propose a multi-step pathway for 
the biogenesis of HIV capsids, in which the assembly 
process can be disrupted at a number of discrete points.
 
T
 
he
 
 protein shell of the human immunodeficiency vi-
rus type 1 (HIV)
 
1
 
 virion, termed the HIV capsid or
core, is composed of 
 
z
 
1,500 copies of the Pr55 Gag
structural protein precursor (for review see Gelderblom,
1991). For proper assembly of the capsid to occur, Pr55
chains must undergo myristoylation (Gheysen et al., 1989;
Gottlinger et al., 1989), an NH
 
2
 
-terminal modification
thought to occur co-translationally (Towler et al., 1988).
The myristoylated chains are targeted to the host plasma
membrane where assembly takes place concomitant with
RNA encapsidation. As capsids are formed, they bud into
the plasma membrane, which results in envelopment and
subsequent release of viral particles from the cell. Coinci-
dent with these events, the immature viral particles un-
dergo a maturation process, involving proteolytic process-
ing of the precursor structural proteins and condensation
of the capsids into collapsed, electron-dense cores (for re-
view see Gelderblom, 1991; Wills and Craven, 1991).
Much of our knowledge of HIV capsid assembly comes
from studies of viral particle formation in cultured cells
transfected with viral genes. EM studies of these cells have
indicated that the plasma membrane is the site of capsid
assembly (Gelderblom, 1991; Wills and Craven, 1991). Anal-
ysis of various mutants of Pr55 have revealed key domains
required for efficient capsid assembly and targeting to the
plasma membrane (Gheysen et al., 1989; Gottlinger et al.,
1989; Trono et al., 1989; Royer et al., 1991; Jowett et al.,
1992; Facke et al., 1993; Wang and Barklis, 1993; Hockley
et al., 1994; Spearman et al., 1994; Zhao et al., 1994).
However, the actual mechanisms involved in coordinating
the formation of an HIV capsid from 1,500 Gag monomers
have not been elucidated. Many important questions about
HIV capsid assembly remain unanswered, including whether
assembly is an energy-dependent process, whether host pro-
teins are required for assembly to take place, and whether
assembly proceeds by way of discrete intermediates.
A major obstacle to addressing these questions experi-
mentally has been the inherent difficulty of studying cap-
sid assembly in cellular systems. In cells, many of the
events in question proceed extremely rapidly and are not
readily amenable to manipulation, making it difficult to
identify 
 
trans
 
-acting factors and energy substrates that
may be required for assembly. Development of a cell-free
system that recreates capsid biogenesis would greatly facil-
itate a biochemical dissection and mechanistic understand-
ing of capsid formation.
In this study, we report the development of a cell-free
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1. 
 
Abbreviations used in this paper
 
: HBV, Hepatitis B Virus; HIV, human
immunodeficiency virus type 1; HSP, high speed pellet; HSS, high speed
supernatant; HSP
 
d
 
, detergent-treated high speed pellet; MCoA, myri-
stoyl CoA.
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system for the assembly of immature HIV capsids that ap-
pears to reproduce known features of capsid structure and
biogenesis, including the phenotypes of a variety of assem-
bly-competent and assembly-defective Gag mutants. We
use this system to demonstrate that capsid formation can
be dissociated into co- and posttranslational phases, each
of which has distinct requirements. The reactions that oc-
cur during the posttranslational phase are dependent on
ATP and at least two independent host factors, distin-
guished by their sensitivity to detergent. In addition, the
posttranslational phase appears to proceed by way of
previously unrecognized assembly intermediates. Expres-
sion of Gag mutants that are defective for assembly results
in accumulation of these assembly intermediates in the
cell-free system. Similar findings are obtained in cellular
systems. Together, these data indicate that HIV capsid
formation is a regulated, energy-dependent, multi-step
process involving 
 
trans
 
-acting host factors.
 
Materials and Methods
 
Plasmid Constructions
 
All plasmid constructions for cell-free transcription were made using PCR
and other standard nucleic acid techniques (Sambrook et al., 1989). Plas-
mid vectors were derived from SP64 (Promega, Heidelberg, Germany)
into which the 5
 
9
 
 untranslated region of 
 
Xenopus laevis
 
 globin had been
inserted at the HindIII site (Melton et al., 1984). The gag ORF from HIV
genomic DNA (a kind gift of Jay Levy, University of California, San Fran-
cisco, CA) was introduced downstream from the SP6 promoter and the
globin untranslated region. The G
 
D
 
A mutation was made by changing
glycine at position 2 of Gag to alanine using PCR. The Pr46 mutant was
made by introducing a stop codon after gly 435 which removes p6; Pr41
has a stop codon after arg 363 (in the COOH-terminal region of p24).
These truncation mutants are comparable to those described by Jowett et
al., 1992. To make the D
 
2
 
 mutant, amino acids from gly 250
 
 
 
through val
260 were deleted (Hockley et al., 1994; Zhao et al., 1994). All changes en-
gineered by PCR were verified by DNA sequencing.
 
Cell-free Reactions
 
Transcription with SP6 polymerase and translation of the transcription
products in wheat germ extract containing [
 
35
 
S]methionine (ICN Bio-
chemicals, Irvine, CA) were performed as previously described (Lingappa
et al., 1994), except for modifications noted below. Improved assembly was
obtained when wheat germ extract, prepared as described before (Erick-
son and Blobel, 1983; Lingappa et al., 1994), was subjected to ultracentrif-
ugation at 50,000 rpm (TLA 100 rotor; Beckman Instruments, Palo Alto,
CA) for 15 min at 4
 
8
 
C and the supernatant used for in vitro translation
(Lingappa, J.R., unpublished observations). 10 
 
m
 
M myristol CoA (MCoA;
Sigma Chemical Co., St. Louis, MO) was added at the start of translation
when indicated. Translation reactions ranged in volume from 20 to 100 
 
m
 
l
and were incubated at 25
 
8
 
C for 150 min. Some reactions were adjusted to
a final concentration of the following agents at times indicated in figure
legends: 0.2 
 
m
 
M emetine (Sigma Chemical Co); 1.0 U apyrase (Sigma
Chemical Co.) per 
 
m
 
l translation; 0.002, 0.1, or 1.0% Nikkol. Results of
some cell-free translation and assembly reactions were repeated using
rabbit reticulocyte lysate that was prepared as described previously
(Merrick, 1983). In pulse–chase experiments, translation reactions con-
tained [
 
35
 
S]cysteine (Amersham Corp., Arlington Heights, IL) for radiola-
beling. 4 min into translation, 3 mM unlabeled cysteine was added, and
the reaction was continued at 25
 
8
 
C for variable chase times, as indicated.
A standard curve for quantity of translation product was established by
immunoblotting a cell-free translation product and standards of known con-
centration (Lingappa, J.R., unpublished observations). The amount of
Pr55 was determined by interpolation on this curve.
 
Gradient Analysis
 
Cell-free reactions were diluted into ice cold NP40 buffer (containing 10
mM TrisAc, pH 7.4, 100 mM NaCl, 4 mM MgAc, 50 mM KAc, and 1%
NP-40) and layered onto the following gradients. All sucrose solutions
were made using the same buffer.
 
2 ml Sucrose Gradients. 
 
After centrifugation (TLS55 rotor; Beckman
Instruments), 200 
 
m
 
l fractions were collected serially from the top. Su-
crose step gradients for batch separation of soluble and particulate material
(used in Figs. 1, 2, and 4) contained 600 
 
m
 
l of 66% sucrose, 900 
 
m
 
l of 40%
sucrose, and 500 
 
m
 
l of 20% sucrose, and were centrifuged at 30,000 rpm
for 35 min at 4
 
8
 
C. Particles of 500–750-S partition into fractions 4–6, which
were collected for further analysis. Linear 10–50% sucrose gradients (used
in Fig. 1) were centrifuged at 30,000 rpm for 35 min at 4
 
8
 
C.
 
2 ml CsCl Gradients. 
 
Equilibrium centrifugation was performed using
2 ml isopycnic CsCl gradients (used in Fig. 1) (402.6 
 
m
 
g/ml) centrifuged at
50,000 rpm for 26 h at 25
 
8
 
C, and 200 
 
m
 
l fractions were collected.
 
13 ml Sucrose Gradients. 
 
13 ml 15–60% linear sucrose gradients were
centrifuged (SW40 Ti rotor; Beckman Instruments) for 75 (Fig. 5) or 95
min (Fig. 3, 6, and 7) at 35,000 rpm and 5
 
8
 
C. Fractions of 350 
 
m
 
l were col-
lected from the top of gradients using a Haake-Buchler gradient fraction-
ator and were processed immediately. Either aliquots of fractions were
loaded directly into SDS-PAGE buffer or the entire fraction was precipi-
tated with TCA and washed with ethanol ether as previously described
(Lingappa et al., 1994) before SDS-PAGE analysis. SDS-PAGE was per-
formed using 15% gels, and some gels were fluorographed using Enhance
(Dupont Co., Willmington, DE). Radiolabeled products of cell-free trans-
lations were visualized by autoradiography.
 
S-value Determinations
 
Estimates of S-values of Gag-containing complexes seen on 13 ml sucrose
gradients were determined by the method of McEwen (1967) using the
following formula: 
 
S
 
 
 
5
 
 
 
D
 
I
 
 / 
 
v
 
2
 
t
 
 where 
 
S
 
 is the sedimentation coefficient of
the particle in Svedberg units, 
 
D
 
I
 
 is the time integral for sucrose at the sep-
arated zone minus the time integral for sucrose at the meniscus of the gra-
dient, 
 
v
 
 is rotor speed in radians/sec, and 
 
t
 
 is time in sec.
Values for 
 
I
 
 were determined for particles of a density of 1.3 g/cm
 
3
 
 and
for a temperature of 5
 
8
 
C, according to tables published by McEwen
(1967). Calculated S-values for different fractions in the gradients are la-
beled as markers above each gradient tracing (Figs. 5–7). Markers such as
BSA (5-S), macroglobulin (20-S), Hepatitis B Virus capsids (100-S), ribo-
somal subunits (40-S and 60-S), and polysomes (
 
.
 
100-S) were used to cal-
ibrate the gradients and to confirm the calculated S-values. However, it
should be noted that the S-value assignments for each Gag-containing
complex are meant to be very approximate estimates that allow a general
description of the complex and should not be interpreted as constituting a
detailed biophysical analysis.
 
Preparation of HSS, HSP, and HSP
 
d
 
Where indicated, wheat germ extract was centrifuged at either 50,000 rpm
for 21 min or 100,000 rpm for 30 min (TLA 100 rotor; Beckman Instru-
ments). The supernatant (HSS) of the 50,000 rpm spin was used for cell-
free translation and assembly reactions. The pellet of the 100,000 rpm spin
(HSP) was resuspended at a 5
 
3
 
 concentration in buffer (25 mM Hepes,
pH 7.4, 4 mM MgAc, 100 mM KAc, 0.25 M sucrose). Wheat germ extract
adjusted to 0.5% Nikkol was subjected to the same ultracentrifugation in
parallel to generate the detergent treated high speed pellet (HSP
 
d
 
). This
pellet was washed twice with 200 
 
m
 
l of the above nondetergent buffer to
remove traces of detergent, and then resuspended. After treatment with
emetine for 50 min, 1.8 
 
m
 
l of HSP or HSP
 
d
 
 was added to the 18 
 
m
 
l cell-free
reactions programmed with HSS. Control reactions were treated with the
same volume of buffer at the same time. At the end of the 150 min incuba-
tion, reactions were separated into soluble and particulate fractions and
analyzed as described above.
 
Transfections and Production of Authentic Capsids
 
Cos-1 cells were transfected by the method of Forsayeth and Garcia
(1994) using plasmids pSVGagRRE-R and pSVRev (Smith et al., 1993)
that were a kind gift of D. Rekosh (University of Virginia, Charlottesville,
VA). 4 d after transfection, immature HIV particles were purified from
the culture medium by sedimentation through a 4 ml 20% sucrose cushion
in an SW 40 rotor at 29,000 rpm for 120 min (Mergener et al., 1992). The
pellet was harvested, stored in aliquots at 
 
2
 
80
 
8
 
C, and treated with 1%
NP-40 buffer just before use to remove envelopes. These de-enveloped,
authentic immature HIV capsids were used as standards and analyzed in
parallel with the products of cell-free reactions by a variety of methods, 
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including velocity sedimentation, equilibrium centrifugation, and electron
microscopy.
Lysate of transfected Cos cells was prepared by solubilizing transfected
cells on 60-mm plates in 700 
 
m
 
l 1% NP-40 buffer. This detergent lysate
was passaged 20 times through a 20-gauge needle, and clarified by centrif-
ugation for 10 min at 2000 
 
g
 
, and 150 
 
m
 
l of this supernatent was loaded
onto 13 ml gradients for analysis, as described. Gag polypeptide present in
the fractions was visualized by immunoblotting with a monoclonal anti-
body to Gag (Dako, Santa Barbara, CA). Bound antibody was detected
using an enhanced chemiluminescence system (Amersham Intl., Amer-
sham, UK). Band density was determined as described under image analy-
sis below, and relative band densities were confirmed by quantitating
films representing different exposure times.
 
Electron Microscopy
 
Cell-free reactions as well as authentic capsid standards were rapidly sepa-
rated into soluble and particulate fractions on 2 ml 20–80% linear sucrose
gradients by centrifugation for 10 min at 30,000 rpm. Under these condi-
tions, authentic capsids partition into fractions 3–5, as determined in ad-
vance by immunoblotting of standards with Gag antibody. EM grids were
glow discharged, and a drop of the Gag antibody was placed on each grid
and allowed to air dry. Grids were inserted into eppendorf tubes contain-
ing particulate material from sucrose gradients and incubated for 10 min
at 4
 
8
 
C to allow antibodies to bind to Gag-containing particles. Grids were
then rinsed in water, and negative staining with uranyl acetate was per-
formed as described (Dubochet et al., 1971). The following negative con-
trols were analyzed in parallel: control transfections, in which Cos cells
were transfected with lac Z-containing plasmids; and mock cell-free reac-
tions, which were generated by programming in vitro transcriptions with
buffer instead of gag cDNA and using this mock transcript for cell-free
translation and assembly reactions. Experiments were repeated three ad-
ditional times in a single blind fashion. In each of these experiments, the
microscopist was able to correctly assign the identity of each sample based
on the presence or absence of particles.
 
Image Analysis
 
Autoradiographs were digitized using an AGFA Focus Color Plus scanner
and Adobe Photoshop software (Adobe Systems Incorporated, Mountain
View, CA). Mean band densities were determined and adjusted for band
size and background.
 
Results
 
Reconstitution of Immature HIV Capsid Assembly in a 
Cell-free System
 
Since we were interested in dissecting the early steps of
capsid assembly rather than the better understood late
stage of capsid maturation, we chose to study formation of
immature HIV capsids, which undergo all of the steps of
capsid assembly except the final protease-dependent mat-
uration event. Assembly of immature capsids in cells re-
quires expression of only the HIV Pr55 protein (Gheysen
et al., 1989; Smith et al., 1993). However, we and others
(Sakalian et al., 1996) have found that standard in vitro
translation systems, consisting of a cytosolic extract, amino
acids, an ATP regenerating system, and in vitro synthe-
sized transcript coding for Pr55 Gag, fail to support assem-
bly of HIV capsids (data not shown). Since assembly of
HIV capsids, as well as assembly of other retroviral cap-
sids, is known to require myristoylation of Gag (Gheysen
et al., 1989; Gottlinger et al., 1989) as well as targeting of
Gag to membranes (Jacobs et al., 1989; Bryant and Rat-
ner, 1990; Rhee and Hunter, 1990; Wang and Barklis,
1993; Platt and Haffar, 1994; Hockley et al., 1994; Spear-
man et al., 1994), we modified the standard system to en-
sure that these events take place. MCoA was added to the
reaction, and cellular extracts were fractionated to opti-
mize capsid assembly. Translation of transcript encoding
Gag in this cell-free system resulted in the synthesis of 
 
z
 
2
ng of Pr55 protein/
 
m
 
l translation reaction (data not
shown).
We expected some of these newly synthesized Pr55
chains to become myristoylated, target to membrane vesi-
cles present in the cellular extract, and assemble into sta-
ble capsids. Other Pr55 chains might achieve some but not
all of the steps in capsid assembly, and would therefore be
detectable as heterogeneous assembly intermediates. To
quantify the amount of assembly, an efficient method of
separating assembled capsids from the remainder of the
translation reaction was required. This was achieved in
two steps. First, after completion of the assembly reaction,
membrane vesicles were solubilized using the nonionic de-
tergent NP-40. This treatment, which removes membranes
enveloping capsids but does not affect the integrity of fully
assembled capsids (Yu et al., 1993; Spearman et al., 1994),
should solubilize unassembled Pr55 chains that may be an-
chored to membranes. Secondly, the detergent-treated,
completed reaction was size fractionated on a sucrose step
gradient into a soluble fraction (containing material of
 
,
 
500-S) and a particulate fraction (containing material
between 500- and 1,000-S) that would be expected to con-
tain completed immature capsids (Royer et al., 1991).
Thus, while our standard translation and assembly reac-
tion was carried out in the absence of detergent to allow
association with membrane vesicles, analysis of the reac-
tion product was performed in the presence of detergent,
allowing the assembly status of the naked proteinacious
capsid to be assessed.
We found that the particulate fraction from a typical
translation and assembly reaction contained between 15
and 40% of the total Pr55 synthesized (see Fig. 2). To as-
sess whether this fraction contained properly assembled
immature capsids, it was further analyzed by velocity sedi-
mentation on linear sucrose gradients, equilibrium centrif-
ugation in CsCl, and EM. For comparison, authentic im-
mature HIV capsids produced in transfected cultured
COS-1 cells were analyzed in parallel. We found that both
detergent-treated capsids generated in the cell-free system
and detergent-treated (de-enveloped) authentic capsids
behaved as a relatively homogenous population of parti-
cles of 
 
z
 
750-S (Fig. 1, 
 
A
 
 and 
 
B
 
), with a buoyant density of
1.36 g cm
 
2
 
3
 
 (Fig. 1, 
 
C
 
 and 
 
D
 
). Additionally, cell-free as-
sembled capsids and the authentic standard were identical
in size as judged by gel filtration (data not shown). When
examined by EM, we found that capsids made in the cell-
free system (Fig. 1 
 
E
 
, 
 
1–4
 
) were morphologically similar to
authentic capsids released from transfected cells (Fig. 1 
 
E
 
,
 
5
 
 and 
 
6
 
) and had the expected diameter of 
 
z
 
100 nm
(Gelderblom, 1991). Thus, on average, 25% of the radiola-
beled Pr55 protein synthesized in the cell-free system as-
sembles into particles that closely resemble authentic im-
mature HIV capsids generated in transfected cells, as
judged by EM appearance as well as the biochemical crite-
ria of size, sedimentation coefficient, and buoyant density.
 
Fidelity of Cell-free HIV Capsid Assembly
 
To determine whether the process of capsid assembly in 
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the cell-free system is the same as that which occurs in
cells, we examined whether known characteristics of cap-
sid assembly were also reconstituted. Studies in cellular
systems have demonstrated that myristoylation of Gag is
required for proper capsid assembly (Gheysen, 1989; Gott-
linger, 1989). This NH
 
2
 
-terminal modification is thought to
occur co-translationally (Wilcox et al., 1987). To assess the
role of myristoylation in the cell-free system we omitted
MCoA from the assembly reaction, or added it posttrans-
lationally at 90 min into the reaction (when 
 
.
 
90% of Pr55
chains have finished synthesis; data not shown). In both
cases, a dramatic decrease in capsid assembly was ob-
served (Fig. 2 
 
A
 
). Consistent with these data, we found
that a Gag mutant that fails to become myristoylated
(G
 
D
 
A) also does not assemble in the cell-free system (see
Fig. 3 
 
B
 
).
In cells, assembly of HIV capsids takes place at the inner
surface of the host cell plasma membrane (Gelderblom,
1991; Wills and Craven, 1991). Membrane targeting of
Pr55 chains is directed by the NH
 
2
 
-terminal myristate moi-
ety and by internal domains of the Pr55 polypeptide (Ja-
cobs et al., 1989; Bryant and Ratner, 1990; Wang and
Barklis, 1993; Platt and Haffar, 1994; Hockley et al., 1994;
Spearman et al., 1994). Studies using Pr55 mutations have
shown that abolishing membrane targeting results in inef-
ficient capsid assembly and failure of capsid release (Ja-
cobs et al., 1989; Bryant and Ratner 1990). For this reason,
targeting to plasma membranes is thought to facilitate the
nucleation of Gag chains at a site within the cell where as-
sembly, envelopment, and budding of the newly formed
capsids can occur. If immature HIV capsid assembly in the
 
Figure 1.
 
Immature HIV capsids synthesized in the cell-free sys-
tem resemble authentic capsids by biochemical and morphologic
criteria. (
 
A
 
 and 
 
B
 
) Migration of capsids on velocity sedimenta-
tion gradients. (
 
A
 
) Cell-free translation and assembly reactions
containing 10 
 
m
 
M MCoA and 
 
35
 
S methionine were programmed
with HIV Gag transcript and performed as described in Materials
and Methods. At the end of the reaction, samples were diluted
into buffer containing 1% NP-40 and separated into soluble and
particulate fractions on sucrose step gradients. Material in the
particulate fraction (
 
.
 
500-S) was further analyzed by a variety of
methods. Shown here is an analysis of the particulate fraction by
velocity sedimentation on a linear sucrose gradient. Radiolabeled
Pr55 protein in the gradient fractions was visualized by SDS-
PAGE and autoradiography. The autoradiograph shows 10 con-
secutive fractions of a gradient with the top of the gradient at the
left side. (
 
B
 
) Cell culture medium was collected from transfected
Cos cells that were releasing immature HIV particles. Virus parti-
cles were harvested by ultracentrifugation through a 20% sucrose
cushion, as described in Materials and Methods. Authentic imma-
ture capsids were generated by treating these harvested particles
with detergent to remove their envelopes. These authentic cap-
sids were sedimented on a velocity sedimentation gradient, in
parallel with the particulate fraction of the cell-free reaction shown
in 
 
A.
 
 Pr55 present in these fractions was visualized by immuno-
blotting. Fractions are displayed in the same order described for
 
A.
 
 (
 
C
 
 and 
 
D
 
) Examination of buoyant density. The particulate
fraction of the cell-free reaction (
 
C
 
) and of authentic immature
capsids (
 
D
 
) was analyzed in parallel by equilibrium centrifuga-
tion on CsCl. Particle density was obtained by measuring the re-
fractive index of each fraction and plotted on the right ordinate
(
 
open circles
 
). Gag polypeptide in the fractions was visualized,
and the amount of protein was determined by densitometry of
bands and plotted on the left ordinate (
 
closed circles
 
). (
 
E
 
) Exami-
nation of electron microscopic appearance. The particulate fraction
of the cell-free reaction (
 
1–4
 
) and authentic capsids (
 
5
 
 and 
 
6
 
)
were incubated on EM grids that were coated with antibody to
HIV Gag. 100-nm particles were visualized by negative staining.  
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cell-free system requires membrane fragments (which are
present in the wheat germ extracts used), it should be sen-
sitive to addition of detergent at concentrations that solu-
bilize membranes. Thus, as a final criterion of authenticity
of the cell-free capsid assembly reaction, we investigated
the sensitivity of cell-free capsid assembly to the presence
of detergent during the translation and assembly reaction.
We treated the assembly reaction with a gentle, nonionic
detergent that does not inhibit any of the enzymatic reac-
tions involved in protein synthesis (Walter and Blobel,
1980) and thus would not be likely to affect protein inter-
actions involved in assembly. As expected, the detergent
Nikkol added to a concentration of 0.1% at the beginning
of the translation reaction had no effect on Gag polypep-
tide synthesis (data not shown). However, as shown in Fig.
2 B, Nikkol at this concentration largely abolished capsid
assembly. This effect was not observed when Nikkol was
used at a concentration of 0.002%, which is below that re-
quired to disrupt lipid bilayers (Walter and Blobel, 1980).
Furthermore, we found that Nikkol added after the com-
pletion of the 150 min assembly reaction did not diminish
the amount of assembly, even when added to a concentra-
tion of 1.0% (data not shown). Thus, it appears that
whereas the completed capsid particle itself is not sensitive
to Nikkol (even at high concentrations), assembly of this
structure is inhibited by concentrations of Nikkol that are
sufficient to solubilize membranes. These data are consis-
tent with the idea that membranes are required for newly
synthesized Pr55 to be efficiently assembled into capsids in
the cell-free system. Thus, the dependence of assembly on
Figure 2. Characteristics of HIV capsid assembly are reproduced
in the cell-free system. (A) Co-translational myristoylation is re-
quired for capsid assembly. Cell-free translation and assembly re-
actions were programmed with Gag transcript in the absence of
added MCoA (2), or with 10 mM MCoA added either at the start
of the reaction (0) or at 90 min into the reaction when translation
is completed (90). The detergent-treated products of the cell-free
reactions were separated into soluble and particulate fractions by
centrifugation on step gradients, and radiolabeled protein in each
fraction was visualized by SDS-PAGE and autoradiography. The
amount of radiolabeled Pr55 in the particulate fraction (which
contains assembled capsids) was determined by densitometry
of bands and is expressed as a percentage of total Gag protein
synthesized. The presence of MCoA had no effect on the total
amount of Pr55 synthesized. Values shown are the average of
three independent experiments, and error bars indicate standard
error. (B) Effect of detergent on capsid assembly. Cell-free trans-
lation and assembly reactions containing 10 mM MCoA were pro-
grammed with Gag transcript. Nikkol, a nonionic detergent that
does not affect protein synthesis, was added at the start of the
translation reaction to a final concentration of 0.002 or 0.1%, as
indicated. At the end of the incubation, the reactions were ana-
lyzed for amount of assembly as in Fig. 2 A. Addition of deter-
gent had no effect on the total amount of Pr55 synthesized. Val-
ues shown are the average of three independent experiments, and
error bars indicate standard error.
Figure 3. Phenotypes of known mutations in Gag appear to be
reproduced in the cell-free system. (A) Diagram of mutations
within Gag. Gag is a polyprotein precursor that consists of four
domains, referred to as p17, p24, p7, and p6. The Pr46 and Pr41
mutants were constructed by introducing a stop codon truncation
at amino acid 435 or at amino acid 363, respectively. In the D2
mutation, amino acids 250 to 260 are deleted. In the GDA muta-
tion, the glycine at amino acid 2 is substituted with an alanine,
thereby blocking myristoylation. The known phenotypes with re-
spect to particle release from cells expressing each of these mu-
tants is indicated to the right. (B) Capsid assembly in cell-free re-
actions programmed with Gag mutants. Cell-free translation and
assembly reactions were programmed with transcript coding for
each of the Gag mutants described above, as well as transcript
coding for wild-type Gag in the presence or absence of MCoA
(labeled WT and 2MCoA, respectively). At the end of the reac-
tion period, each sample was detergent treated, fractionated by
velocity sedimentation on 13 ml sucrose gradients, and analyzed
by SDS-PAGE and autoradiography. The amount of radiola-
beled translation product in the position of completed 750-S
capsids was quantitated by densitometry and expressed for each
reaction as a percentage of total synthesis. The total amount of
translation was approximately equal in all reactions.The Journal of Cell Biology, Volume 136, 1997 572
cotranslational myristoylation and the apparent require-
ment for membranes indicate that capsid assembly in the
cell-free system faithfully reproduces characteristics of
capsid assembly that have been described in cellular systems.
Studies of capsid assembly in cell culture model systems
have revealed that certain mutations within the Gag cod-
ing region disrupt immature HIV capsid assembly. As a
third criterion for fidelity, we examined the assembly phe-
notypes in the cell-free system of four previously de-
scribed mutations in Gag (Fig. 3 A): (a) the Pr46 mutant,
in which the COOH-terminal p6 domain of Gag is deleted
(Royer et al., 1991; Jowett et al., 1992; Hockley et al., 1994;
Spearman et al., 1994); (b) the Pr41 mutant, in which the
deleted domains include p6, p7, and the distal end of p24
containing the p24–p7 protease cleavage site (Gheysen et al.,
1989; Jowett et al., 1992; Hockley et al., 1994); (c) the D2
mutation, in which 10 amino acids of the p24 domain of
Gag (upstream of the p24-p7 protease cleavage site) are
deleted (Hockley et al., 1994; Zhao et al., 1994); and (d)
the GDA mutation, an NH2-terminal single amino acid sub-
stitution that abolishes myristoylation of Gag (Gottlinger
et al., 1989; Bryant and Ratner, 1990). Upon expression in
cells, only the Pr46 mutant was capable of producing viral
particles indistinguishable from those produced by expres-
sion of wild-type Gag (Royer et al., 1991; Jowett et al.,
1992; Hockley et al., 1994; Spearman et al., 1994). Each of
the other three mutants fails to result in proper viral parti-
cle production and release (Gheysen et al., 1989; Gott-
linger et al., 1989; Bryant and Ratner, 1990; Jowett et al.,
1992; Hockley et al., 1994; Zhao et al., 1994).
Assembly reactions were programmed with transcript
encoding each of these mutations and the amount of im-
mature capsid produced was quantitated as described in
the legend of Fig. 3. As is shown in Fig. 3 B, the Pr41 and
GDA mutants failed to assemble into completed capsids,
while z40% of the total translation product of the assem-
bly-competent Pr46 mutant and wild-type Gag assembled
into completed capsids. The D2 mutant appeared to have
generated a small amount of material in the region of com-
pleted capsids, but further analysis of this material re-
vealed it to be the trail of a large Gag complex (of z400–
500 S) that does not comigrate with completed capsid (see
Fig. 6 E). Thus, like Pr41 and GDA, D2 did not assemble
into the 750-S completed capsid. Together, these data indi-
cate that the cell-free system appears to faithfully repro-
duce phenotypes of a variety of assembly-defective and
-competent mutations in Gag.
Posttranslational Requirements for Capsid Assembly
For optimum assembly to occur, the cell-free reaction must
be incubated at 258C for at least 150 min (data not shown).
We observed that whereas the majority of Pr55 synthesis
occurs during the first hour of this incubation, significant
capsid formation does not take place until the final 90 min
of the reaction. Thus, an aliquot of the reaction incubated
for only 50 min contains z60% of the full length Pr55 chains
that are present in an aliquot incubated for the standard
150 min (data not shown). However, essentially none of
the chains present at the 50 min time point has assembled
into capsids (data not shown), while at 150 min 25% have
completed the assembly process (Fig. 4 A). This indicated
to us that it might be possible to completely separate the
translation and assembly phases of the reaction. To con-
firm this, a reaction was split into two aliquots at 50 min
into the incubation. To one aliquot we added emetine, which
blocks translation by inhibiting chain elongation, and then
both aliquots were incubated to 150 min. While total Pr55
synthesis in the emetine-treated reaction was 60% of the
control (Fig. 4 A, compare gel lanes 1 and 2), the propor-
tion of capsid assembly in this treated reaction was compa-
Figure 4. Both ATP and a subcellular fraction of the cell lysate
are required for capsid assembly. (A) Effect of ATP hydrolysis
on the posttranslational phase of capsid assembly. As in Fig. 2 B,
cell-free translation and assembly reactions were programmed
with Pr55 in the presence of 10 mM MCoA. At 50 min into trans-
lation, 0.2 mM emetine, a protein synthesis inhibitor, was added
to some reactions as indicated. Immediately after emetine treat-
ment, apyrase, an enzyme that hydrolyzes ATP, was added at a
concentration of 1 U/ml to one of the emetine-treated reactions.
At the end of the incubation (150 min), 1 ml of each reaction was
analyzed directly by SDS-PAGE (autoradiographs are shown be-
low bar graph). The remainder of the products was analyzed for
amount of assembly as described in Fig. 2. Shown in the bar
graph is the amount of Pr55 assembled as a percentage of total
Pr55 synthesized in each reaction. Values in the bar graph are the
average of three independent experiments, and error bars indi-
cate the standard error. (B) Effect on assembly of depletion and
reconstitution of a subcellular fraction. Wheat germ extract was
subjected to ultracentrifugation as described in Materials and
Methods to generate the HSS, HSP, and HSPd. The HSS was used
to program cell-free translation and assembly reactions in the
presence or absence of 10 mM MCoA (as indicated). Each of
these reactions was treated with the protein synthesis inhibitor
emetine for 50 min. After this, the HSP or HSPd was added to al-
iquots of the reaction as indicated below the bar graph. All reac-
tions were incubated for a total of 150 min. A 1 ml aliquot was re-
moved and analyzed directly by SDS-PAGE (shown below bar
graph). The remainder of each reaction was analyzed for amount
of assembly as described in Fig. 2 and plotted as a percentage of
total Pr55 present in each reaction. The values shown in the bar
graph are the average of three independent experiments, and er-
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rable to that of the untreated control (Fig. 4 A, bar graph),
indicating that assembly takes place even when translation
is halted. Based on these data, one would expect that ma-
nipulations performed after emetine treatment would
have effects on only the posttranslational phase of assem-
bly and should not affect Pr55 synthesis, which is already
completed.
Having established a means of analyzing events specific
to assembly, we then examined whether the previously de-
scribed detergent sensitivity of HIV capsid assembly (Fig.
2 B) was due to an effect on co- or posttranslational events.
We treated Pr55 reactions with emetine and 0.1% Nikkol
at 50 min into the reaction, continued the incubation to
150 min, and then determined the amount of assembly as
previously described. Under these conditions, assembly
was dramatically reduced (data not shown), just as it had
been when Nikkol was added at the start of translation
(Fig. 2 B). Therefore, we conclude that the detergent sen-
sitive step(s) in HIV capsid assembly occurs posttransla-
tionally.
Next we examined whether posttranslational events in
capsid assembly are dependent on the presence of ATP.
Translation of Gag was allowed to proceed for 50 min, at
which point further protein synthesis was inhibited with
emetine. The sample was divided, and one aliquot was de-
pleted of ATP by the addition of apyrase, an enzyme that
hydrolyzes free ATP. After completion of the assembly re-
action, samples were analyzed as previously described for
the amount of assembly that had occurred. We found that
depletion of free ATP from the assembly reaction resulted
in a dramatic reduction in capsid assembly (Fig. 4 A, bar
graph). The effect of ATP depletion was not reversed by
addition of the nonhydrolyzable analogues, AMP-PNP or
GTPg-S (data not shown), suggesting that ATP hydrolysis,
and not just ATP binding, is required. As expected, addi-
tion of apyrase did not change the total amount of Pr55
synthesis (Fig. 4 A, compare gel lanes 2 and 3). Further-
more, adding apyrase to the reaction after capsid assembly
was completed had no effect on the amount of assembly
(data not shown), ruling out the possibility of an effect of
apyrase or ATP depletion on capsid stability. These data
indicate that there is a requirement for ATP in the capsid
assembly process, and that this ATP dependence is distinct
from the energy requirements of protein synthesis.
A Subcellular Fraction Is Required for Capsid Assembly
Given that the Gag protein itself is not known to bind or
hydrolyze ATP, the requirement for this energy substrate
suggests that a host protein or proteins are involved in the
assembly reaction. Demonstrating that such a host factor
is required would involve showing that assembly fails to
occur when this factor is depleted from the cellular ex-
tracts used in the assembly reaction. Furthermore, adding
back the depleted fraction to the reaction should restore
assembly. Thus, we sought to fractionate the translation
extract in a manner that would leave intact all of the com-
ponents needed for translation but remove at least one
component required for assembly. The cellular extract
used for translation and assembly was subfractionated by
ultracentrifugation into two portions: HSS and HSP. The
HSS, depleted of components that were 90-S or greater,
supported Pr55 translation but not its assembly (Fig. 4 B).
This indicates that the HSP likely contains an assembly
specific host factor(s). This was demonstrated directly by
showing that addition of the HSP posttranslationally (after
emetine treatment) to unassembled Gag chains synthe-
sized in the HSS resulted in a considerable restoration of
particle assembly (Fig. 4 B). As expected, total synthesis of
Pr55 was unaltered by addition of the HSP (Fig. 4 B, gel).
Together, these data indicate that a subcellular fraction of
the eukaryotic cell lysate is required for posttranslational
events in capsid assembly to take place.
We had previously observed that detergent also disrupts
the posttranslational phase of capsid assembly (data not
shown). We examined, therefore, whether the HSP con-
tained the detergent-sensitive component that is required
for capsid formation. HSP was prepared from a cell extract
treated with detergent (0.5% Nikkol). The resulting HSP
was washed with detergent-free buffer and added post-
translationally to an assembly reaction. We found that the
HSP from the detergent-treated extract was as active in
promoting posttranslational capsid formation as the control
HSP (Fig. 4 B, bar graph). Thus, separate detergent-sensi-
tive and -insensitive host factors appear to be involved in
the posttranslational phase of HIV capsid assembly. Fur-
thermore, the detergent-insensitive host factor can be de-
pleted by ultracentrifugation and then reconstituted by
posttranslational addition.
Intermediates in the Assembly of HIV Capsids
The existence of multiple specific requirements for HIV
capsid biogenesis, including host factors and ATP, sug-
gests that discrete biochemical intermediates may exist
during the assembly process. To date, such intermediates
in capsid assembly have not been described, most likely
due to the difficulty of detection in cellular systems where
they would be present only transiently and in minute
quantities. Since the cell-free system is less efficient at
forming completed capsids than are cellular systems, it
might constitute a better system for detecting such assem-
bly intermediates. Consistent with this possibility, we
found that under conditions where only a small amount of
750-S capsid assembly occurs in the cell-free reaction,
analysis of the reaction products on 13 ml velocity sedi-
mentation gradients revealed the presence of a series of
Gag-containing complexes, in addition to 750-S completed
capsids (Fig. 5 A). These complexes, which have calculated
sedimentation coefficients of z10-S, 80-S, and 150-S, will
henceforth be referred to as complexes A, B, and C, re-
spectively.
If these complexes represent assembly intermediates,
they would be expected to be present in large quantities at
early time points, and to be diminished at later times in the
reaction. To assess whether these complexes displayed this
behavior, we used a pulse–chase analysis to follow a small
cohort of radiolabeled Pr55 chains over time. The cell-free
reaction was performed with radiolabeled cysteine. After
the first 4 min of translation, an excess of unlabeled cys-
teine was added to abolish further labeling of subse-
quently synthesized Pr55 chains. We observed that the to-
tal amount of radiolabeled Pr55 was the same at 25 and
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that neither further radiolabeling nor degradation of Pr55
had occurred after 25 min and confirming that the same
population of Pr55 chains was being analyzed at both
times. Aliquots of the cell-free reactions were removed at
the times indicated, treated with detergent, and then ana-
lyzed on 13 ml velocity sedimentation gradients.
At 25 min into the reaction, all of the radiolabeled Pr55
was found in complexes A, B, and C (Fig. 5 C), with no ra-
diolabeled Pr55 present in the region of completed 750-S
capsids. While complexes A and B appear as peaks at z
the 10-S and 80-S positions of the gradient, complex C ap-
pears as a less distinct shoulder in approximately the 150-S
position. In marked contrast, examination of the assembly
reaction at 150 min showed that a significant amount of ra-
diolabeled Pr55 was assembled into completed capsids
that migrated in the 750-S position (Fig. 5 D). Correspond-
ingly, the amount of Pr55 in complexes A, B, and C was di-
minished by precisely the amount that was now found to
be assembled, demonstrating that at least some of the ma-
terial in complexes A, B, and C constitutes intermediates
in the biogenesis of completed 750-S capsids.
At extremely short chase times (i.e., 13 min), when only
some of the radiolabeled chains have completed synthesis,
full length Pr55 chains were found exclusively in complex A
on 13 ml sucrose gradients, while nascent chains that are
not yet completed were in the form of polysomes of greater
than 100-S (data not shown). Thus, polysome-associated
nascent chains of Gag constitute the starting material in
this pathway, and the 10-S complex A, which contains
completed Gag chains, is likely to be the first intermediate
in the formation of immature capsids. It is possible, there-
fore, that complexes B and C represent later assembly in-
termediates in the pathway of capsid formation.
If complexes A, B, and C do in fact constitute intermedi-
ates in assembly, one would predict that blockade of as-
sembly would result in accumulation of Gag chains in the
form of complexes with those S values. Furthermore, one
would expect that blockade at different points along this
pathway would result in accumulation of complexes A, B,
and C in various combinations, as determined by the order
of their appearance along the assembly pathway. For ex-
ample, if an ordered pathway of intermediates exists, then
blockade at early points in the pathway should result in ac-
cumulation of one or two Gag-containing complexes cor-
responding to early putative assembly intermediates, while
blockade at a very late point in the pathway would result
Figure 5. Pulse–chase analy-
sis of HIV capsid assembly.
(A) Analysis of a continu-
ously labeled cell-free reac-
tion by velocity sedimenta-
tion. Cell-free translation
and assembly of Pr55 were
performed as previously de-
scribed. Upon completion of
the cell-free reaction, the
products were diluted in 1%
NP-40 sample buffer on ice
and were analyzed by velocity
sedimentation on 13 ml 15–
60% sucrose gradients. Frac-
tions were collected from
the top of each gradient as
described in Materials and
Methods, and the amount of
radiolabeled Pr55 protein in
each fraction was determined
and expressed as a percentage
of total Pr55 protein present
in the reaction. The calcu-
lated positions of 10-, 80-,
150-, 500-, and 750-S com-
plexes are indicated with
markers above (see Materials
and Methods). 750-S repre-
sents the position of authen-
tic immature (de-enveloped)
HIV capsids. (B–D) Analysis
of a pulse–chase cell-free re-
action by velocity sedimenta-
tion. Cell-free translation
and assembly of Pr55 were performed as previously described, except that [35S]cysteine was used for radiolabeling. At 4 min into trans-
lation, an excess of unlabeled cysteine was added to the reaction so that no further radiolabeling would occur. Aliquots of the reaction
were collected 25 (C) and 150 min (D) into the reaction. 1 ml of each aliquot was analyzed by SDS-PAGE and autoradiography to re-
veal the total amount of radiolabeled Pr55 translation product (B, arrow) present at each chase time. The remainder of the aliquots was
diluted into 1% NP-40 sample buffer on ice and analyzed by velocity sedimentation on 13 ml 15–60% sucrose gradients (5, C and D, re-
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in accumulation of all the putative assembly intermediates
but not the final completed capsid product. To test these
predictions, we blocked assembly in a variety of ways,
both pharmacologically and through the use of mutations,
and examined the Gag-containing complexes that were
formed.
Pharmacological Blockade Results in Accumulation of 
Assembly Intermediates
Capsid assembly was disrupted by adding either apyrase
posttranslationally (as in Fig. 3) or detergent co-transla-
tionally (as in Fig. 2), and the reaction products were ana-
lyzed by velocity sedimentation as described for Fig. 5.
Material in fractions corresponding to the assembly inter-
mediates and completed capsid were quantified and are
presented in Table I. The untreated reaction contained
Pr55 in complexes A, B, and C, as well as a peak in the fi-
nal 750-S capsid position, while the treated reactions, as
expected, contained no peak at the position of the final
capsid product (Table I). Treatment with either apyrase or
detergent resulted in accumulation of additional material
in complexes B and C, but did not result in accumulation
of additional material in complex A. This is consistent with
the idea that complexes B and C are the more immediate
precursors of the 750-S completed capsids, and that these
interventions block the conversion of complexes B and C
into the fully assembled capsid end product.
Assembly-defective Mutants Are Arrested at Specific 
Points in the Assembly Pathway
To determine whether the putative assembly intermedi-
ates accumulate when capsid assembly is blocked by speci-
fic mutations in Gag, cell-free reactions were programmed
with each of the previously described assembly-competent
and -defective Gag mutants (Fig. 3), incubated for 150 min,
and then analyzed by velocity sedimentation. Reactions
programmed with wild-type Gag (Fig. 6 A) or the assem-
bly-competent Pr46 mutant (Fig. 6 B) were found to have
nearly identical profiles, in which .30% of the radiola-
beled Gag chains synthesized formed completed immature
capsids (that migrate at 750-S), and the remainder was in
the form of residual putative assembly intermediates A
and B. Thus, these two assembly-competent forms of Gag
appear to be indistinguishable in the cell-free system just
as they are when expressed in cells (Royer et al., 1991;
Jowett et al., 1992; Hockley et al., 1994; Spearman et al.,
1994).
Fig. 6 C shows the same analysis for the assembly defec-
tive Pr41 mutant. We found that all of the radiolabeled
chains at the end of the Pr41 cell-free reaction were con-
tained in a single complex that peaks at z10-S and corre-
sponds to complex A. Since the 10-S peak was very large
and led to an irregular trail that could be masking 80- or
150-S peaks, we reanalyzed the products of a Pr41 reaction
on a gradient that allowed high resolution in the 1–200-S
size range (data not shown) and confirmed that all of the
Pr41 translation product was present in complex A, which
was z10-S in size. Thus, in the cell-free system, it appears
that Pr41 fails to progress beyond complex A, which is likely
to represent the first intermediate in the assembly pathway.
Like Pr41, the myristoylation-incompetent GDA mutant
failed to assemble into 750-S capsids (Fig. 3 B and Fig. 6
D), but unlike Pr41, GDA had distinct peaks in both the
10- and 80-S regions of the gradient (Fig. 6, compare D to C).
These data indicate that the GDA mutant, which contains the
entire Gag coding region except for the myristoylation sig-
nal, is capable of forming complex A, which appeared to
be the first assembly intermediate in the pulse–chase ex-
periment, as well as complex B, but does not progress fur-
ther towards forming completed capsids. These data suggest
that complex B is likely to be the second assembly inter-
mediate formed in the biogenesis of immature HIV capsids.
Previously, we had shown that in the absence of exoge-
nously added MCoA, wild-type Gag failed to assemble in
the cell-free system (Fig. 2 A), consistent with previous
observations that myristoylation is required for proper
capsid assembly to occur. Thus, a cell-free reaction pro-
grammed with wild-type Gag but performed in the ab-
sence of MCoA would be expected to be blocked at the
same point in the assembly pathway as the GDA mutant.
Consistent with this, we found that assembly performed in
the absence of MCoA resulted in formation of only com-
plexes A and B (data not shown), and therefore closely re-
sembled the GDA mutant shown in Fig. 2 D.
Analysis of a cell-free reaction programmed with the D2
mutant is shown in Fig. 2 E. Unlike the previously de-
scribed assembly-defective mutants, D2 was found to form
a spectrum of Gag-containing complexes, including peaks
corresponding to complexes A and B (at z10- and 80-S), a
shoulder corresponding to complex C (in the 150-S re-
gion), and an additional peak of z400–500-S, that will
henceforth be referred to as complex D. Note that com-
plex D trails into the 750-S region, accounting for the ap-
pearance of a small amount of assembly in the simpler
analysis presented in Fig. 1. However, the detailed analysis
presented here makes it clear that in fact there is no dis-
crete peak in the region of completed capsid (750-S).
Thus, the D2 mutant appears to form a series of complexes
corresponding in size to the assembly intermediates seen
in the pulse–chase experiment (Fig. 5), as well as an addi-
tional complex of larger size, but fails to produce the com-
pleted 750-S product.
Gag-containing Complexes within Mammalian Cells
Having demonstrated by pulse–chase analysis, pharmaco-
logic blockade, and analysis of mutants that assembly in-
Table I. Effect of ATP Hydrolysis and Detergent Treatment on 
Assembly Intermediates
A B/C
Final
capsid
Untreated 2,798 5,046 739
1 Apyrase 2,851 5,999 133
1 Detergent 2,656 6,130 189
Cell-free translation and assembly reactions were programmed with Pr55 in the pres-
ence of 10 mM MCoA. One reaction was treated with emetine for 50 min followed by
apyrase (as described in Fig. 4), and a second reaction was treated with the detergent
Nikkol to a final concentration of 0.1% added at the start of translation (as described
in Fig. 2 B). The control reaction was untreated. Reactions were incubated for 150
min, diluted into 1% NP-40 sample buffer on ice, and analyzed in parallel by velocity
sedimentation on 13-ml 15–60% sucrose gradients. Fractions were collected, and the
amount of radiolabeled Pr55 protein present in the complexes A, B, and C and final
completed capsid was determined. Note that material present in the 750-S region of
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termediates appear to exist in the cell-free system, we then
examined whether complexes of the same sizes are present
in mammalian cells that are expressing wild-type Gag or
Gag mutants. The finding of such complexes would be
consistent with the existence of similar transient interme-
diates in vivo.
Cos cells transfected with wild-type Gag were lysed in
detergent, and the lysate was analyzed on 13 ml velocity
sedimentation gradients, as in Figs. 5 and 6. Gradient frac-
tions were immunoblotted with Gag antibody, and the rel-
ative amount of Gag polypeptide present in each fraction
was quantitated as described in Materials and Methods
(Fig. 7 A, closed circles). The cell lysate contained Pr55 in
a spectrum of complexes ranging from 10- to z200-S.
Since cells efficiently release completed HIV capsids, most
of the completed capsid would be expected to be in the
medium at steady state. This was confirmed by the finding
that a substantial amount of fully assembled 750-S capsid
was present in the medium (Fig. 7 A, open circles), while
the cell lysate contained no 750-S capsids (Fig. 7 A, closed
circles). We conclude, therefore, that within cells, Pr55 is
present in a heterogeneous mixture of complexes that
have S values similar to complexes A, B, and C, the assem-
bly intermediates found in the cell-free system.
If these complexes correspond to the assembly interme-
diates seen in the cell-free system, one would expect that
different assembly-defective mutants would result in the
accumulation of the same sized complexes in cellular sys-
tems as they do in the cell-free system. Thus, we examined
whether the Pr41 mutant, which appears to be blocked af-
ter the first assembly intermediate in the cell-free system,
and the D2 mutant, which appears to be blocked at the
end of the assembly pathway in the cell-free system, re-
sulted in corresponding patterns of Gag-containing com-
plexes within cells. Cos cells were transfected with each of
these mutants, and the medium as well as the lysate were
examined by immunoblotting. As expected, medium from
cells transfected with the assembly-defective Pr41 or D2
did not contain 750-S completed capsids (data not shown).
The cell lysate of Cos cells transfected with the Pr41 mu-
tant contained only material that peaked in the 10-S re-
gion of the velocity gradient (Fig. 7 B), resembling what
had been found when the Pr41 mutant was expressed in
the cell-free system (Fig. 6 C). The observation that the
Pr41 reaction product migrated as a single complex that
peaked in the 10-S region was confirmed by analysis on a
variety of different velocity sedimentation gradients that
allowed higher resolution in the 1–200-S size range (data
not shown). In contrast, the cell lysate of Cos cells trans-
fected with the D2 mutant contained a spectrum of immu-
noreactive complexes that ranged in size from 10–500-S
(Fig. 7 C), resembling what had been found when D2 was
expressed in the cell-free system (Fig. 6 E). Thus, the data
from transfected cells suggests that the behavior of Gag
mutants in the cell-free system reflects events in capsid as-
sembly that occur in living cells.
Figure 6. Different assembly-defective
mutants in Gag accumulate different
assembly intermediates. Cell-free
translation and assembly reactions
were programmed with wild-type
Gag (A), the assembly-competent
Pr46 truncation mutant (B), the as-
sembly-defective Pr41 truncation mu-
tant (C), the assembly-defective
GDA mutant (D), or the assembly-
defective D2 mutant (E). At the end
of the incubation, reaction products
were detergent treated and analyzed
by velocity sedimentation on 13 ml
sucrose gradients as in Fig. 5 A. The
amount of radiolabeled translation
product in each fraction was deter-
mined and expressed as a percentage
of total synthesis for each reaction.Lingappa et al. Multistep Pathway for Assembly of HIV Capsids 577
Discussion
In this paper, we first demonstrate that immature HIV
capsids can be assembled in a cell-free system. We estab-
lish that the capsids produced closely resemble immature
HIV capsids produced in cellular systems (Fig. 1) and that
key known features of capsid assembly are faithfully re-
produced in this cell-free system (Figs. 2 and 3). We then
use it to dissect assembly into a number of steps. First,
through the use of an inhibitor of protein synthesis, we
demonstrate that assembly can be resolved into a co-trans-
lational phase, during which Pr55 polypeptides are synthe-
sized, followed by a posttranslational phase, during which
additional events necessary for assembly take place. Being
able to separate these two phases allows us to analyze re-
actions specific to the assembly process, independent of
other events such as protein synthesis.
By manipulating the posttranslational phase of assem-
bly, we then demonstrate that it has at least three specific
requirements (Fig. 4). First, ATP is necessary, since the
enzyme apyrase is able to effectively block the posttransla-
tional progression of completed Pr55 chains into fully as-
sembled capsids. Second, this phase is sensitive to non-
ionic detergent, implying that membrane fragments are
likely to be involved. Third, using a depletion and recon-
stitution approach, we demonstrate that a subcellular frac-
tion of eukaryotic cell lysate is required for the posttrans-
lational assembly events to take place.
In addition, multiple criteria are used to demonstrate
that the posttranslational phase of assembly proceeds by
way of a series of Gag-containing complexes that appear
to constitute intermediates in the cell-free capsid assembly
reaction (Figs. 5 and 6 and Table I). Finally, we show that
complexes resembling assembly intermediates may also be
present in cellular systems that are producing immature
HIV particles, and that mutants in Gag have a similar be-
havior in both cellular and cell-free systems (Fig. 7).
Novel Requirements for HIV Capsid Assembly
To date, studies have not revealed whether HIV capsid as-
sembly occurs by way of a passive process of Gag polypep-
tide multimerization, or whether assembly is an active,
regulated process requiring Gag associations with other
proteins, as well as Gag–Gag interactions. By demonstrat-
ing that the posttranslational phase of assembly requires
ATP and a detergent-insensitive host cell component, our
Figure 7. Gag-containing complexes in cells transfected with
wild-type Gag or assembly-defective Gag mutants. (A) Cos-1 cells
were transfected with a transfection vector encoding Pr55 cDNA,
as described in Materials and Methods. 4 d later, the medium
from the cells was collected. Viral particles in the medium were
harvested by ultracentrifugation through a 20% sucrose cushion
and then treated with detergent to remove envelopes. The trans-
fected cells were solubilized in detergent to generate the cell ly-
sate (see Materials and Methods). The particles from the medium
(right ordinate, open circles) and the detergent lysate of the cells
(left ordinate, closed circles) were analyzed in parallel by velocity
sedimentation on 13 ml 15–60% sucrose gradients, as in Fig. 5.
The amount of Pr55 protein in each fraction of these gradients
was determined by immunoblotting and expressed as a percent-
age of total Pr55 protein present. The calculated positions of 10-,
80-,150-, 500-, and 750-S complexes are indicated with markers
above (see Materials and Methods). 750-S represents the position
of authentic, immature (de-enveloped) HIV capsids. (B and C)
Cos-1 cells were transfected with a transfection vector encoding
the Pr41 mutant (B) or the D2 mutant (C). Transfected cells were
lysed in detergent, and the lysate was analyzed by velocity sedi-
mentation on 13 ml sucrose gradients, as in A above. The amount
of capsid protein in each fraction of these gradients was deter-
mined by immunoblotting with anti-Gag antibody, and was ex-
pressed as a percentage of total immunoreactive protein present
in each reaction.The Journal of Cell Biology, Volume 136, 1997 578
data indicate that in fact HIV capsid assembly is an energy-
dependent, coordinated process in which host proteins
play a crucial role. Thus, the model of HIV capsid assem-
bly supported by our data is conceptually very different
from the view that many viral capsids are formed from
capsid monomers by way of a passive process of “self as-
sembly,” requiring no components besides the individual
capsid protein subunits (Klug, 1980). Indeed, while host
factors have not previously been documented to play a
role in the assembly of HIV capsids, the possibility of their
existence has been raised by data demonstrating that yeast
expressing Gag do not support HIV capsid assembly (Ja-
cobs et al., 1989), while baculovirus and mammalian sys-
tems of expression do (for review see Boulanger and
Jones, 1996). Such studies imply that yeast either contain a
factor that inhibits HIV capsid assembly (that is absent in
higher eukaryotes) or lack a factor necessary for assembly
(that is present in higher eukaryotes). Our data support the
latter possibility. Consistent with the notion that previ-
ously unrecognized host factors may be important at vari-
ous points in the HIV life cycle is the recent demonstra-
tion that cyclophilins are associated with the HIV virus
particle and are required for infectivity (Luban et al., 1993;
Franke et al., 1994; Thali et al., 1994).
The finding that HIV capsid assembly requires ATP as
well as host cell components suggests that the posttransla-
tional phase of assembly may occur via a step-wise path-
way of previously unrecognized assembly intermediates.
We present three lines of evidence to support this view.
First, using a pulse–chase analysis we demonstrate that a
population of lower molecular weight Gag-containing com-
plexes, referred to as complexes A, B, and C, is present at
early time points in capsid assembly, and that Gag poly-
peptides from this population are converted into the final
capsid product over time. Note that the possibility that
these complexes represent polyribosomes has been ruled
out by the demonstration that they are not sensitive to
RNase A used at concentrations that result in complete di-
gestion of messenger RNA (Lingappa, J.R., unpublished
observations). At very short chase times, all of the radiola-
beled Pr55 in the pulse–chase reaction is present in com-
plex A, suggesting that this may be the first intermediate
in the assembly reaction, appearing after completed Gag
chains are released from ribosomes. It remains to be deter-
mined whether complex A constitutes either a monomer
or dimer of Gag, or whether it is composed of a Gag chain
associated with a host protein.
Secondly, we show that by blocking assembly pharmaco-
logically, using either apyrase or detergent, material in two
of these complexes (complexes B and C) accumulates, in-
dicating that they are likely to be precursors to the com-
pleted 750-S capsid end product. Note that these data do
not exclude the existence of other intermediates that might
occur later in the pathway. Such intermediates would not
be seen with apyrase or detergent blockade, since these
agents appear to block assembly by preventing progres-
sion beyond the 150-S complex. The demonstration that
both detergent and ATP depletion appear to result in the
accumulation of the same assembly intermediates raises
the possibility that this point in the assembly pathway may
be a critical one, in which a variety of events necessary for
assembly must take place in a coordinated fashion. Fur-
ther work will be required to determine whether this rep-
resents an important point of regulation in the assembly
pathway.
Finally, the analysis of three different Gag mutants that
are known to be assembly defective lends further support
to the presence of assembly intermediates. We find that
each mutant results in the accumulation of different sub-
sets of these assembly intermediates. Thus, a mutant that
appears to be blocked after the first step in the assembly
pathway results in the accumulation of complex A alone
(Fig. 6 C), while one that appears to be blocked after the
second step of the pathway results in accumulation of com-
plex A and complex B (Fig. 6 D). A spectrum of com-
plexes, including complexes A, B, and C, as well as the
larger complex D, is seen upon expression of a mutant that
appears to be blocked at a very late step in the assembly
pathway (Fig. 6 E). Thus, analysis of these mutants sup-
ports the existence of intermediates in the assembly of HIV
capsids, and also suggests an order to the appearance of
such intermediates during the process of capsid assembly.
There are a number of caveats to our demonstration of
assembly intermediates. First, one or more of these puta-
tive intermediates could in fact constitute a side reaction
or dead end byproduct off the main pathway of capsid as-
sembly. The most likely candidate for such a dead-end
byproduct is complex D, which is only clearly apparent in
the analysis of the assembly-defective D2 mutant (Fig. 6 E).
Arguing against the possibility that complexes A, B, or C
are simply nonproductive side reactions is the finding that
the amount of each of these complexes varies inversely
with the amount of completed, immature capsid formed.
Such behavior would be expected for assembly intermedi-
ates but not for dead-end byproducts or side reactions.
For example, the quantity of each of these complexes de-
creases over time in the pulse–chase experiment, during a
period when completed capsids are appearing and the to-
tal number of radiolabeled Gag chains present is constant
(Fig. 5). Likewise, complexes B and C increase in quantity
when formation of capsids is blocked (Table I). Addition-
ally, in an analysis of a mutant that is more efficient in
capsid production than wild-type cells, we find that the
amount of complex A drops to very low levels when very
large amounts of capsid are being made (Hill, R.L., and
J.R. Lingappa, unpublished observation). Thus, the sim-
plest interpretation of our data is that the Gag complexes
A, B, and C constitute true assembly intermediates, al-
though definitive proof of this must await a functional ex-
amination of each of these intermediates in isolation.
A second caveat is that our analysis could be compli-
cated by instability of Gag-containing complexes. Thus,
lower molecular weight complexes could actually result
from disassembly of a higher order complex. This seems
unlikely to be a significant problem in our system, given
that we have not observed any of the Gag-containing com-
plexes to be labile in our studies. For example, in the pulse–
chase experiments (Fig. 5), there is a clear-cut progression
over time from complexes A, B, and C to completed im-
mature capsids. Residual amounts of complexes A and B
present at the end of the incubation are likely due to in-
complete conversion resulting from depletion and inacti-
vation of necessary factors over time.
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ist additional intermediates in HIV capsid assembly that
are not obvious from our current analysis. Finally, we wish
to point out that the S-values assigned to each of the com-
plexes described here are only approximate S-values, cal-
culated from the migration of these complexes in velocity
sedimentation gradients (see Materials and Methods). While
one or more complexes may not appear to be distinct in
a particular experiment or a particular gradient (i.e., the
150-S complex in Fig. 5 C), the specific complexes de-
scribed here have been seen repeatedly in many different
experiments and under a variety of gradient conditions
and therefore are likely to represent discrete complexes
that are difficult to resolve perfectly in every experiment
given their transient and dynamic nature.
A Multi-step Pathway for the Assembly of HIV Capsids
Together, our results support a model of capsid assembly
as a stepwise process consisting of discrete biochemical
events with specific requirements for ATP and at least one
detergent-insensitive component of eukaryotic cell lysate.
The model in Fig. 8 presents the simplest scenario that uni-
fies the data presented here. While further analysis of this
system may reveal additional complexities, this scheme
presents a biochemical framework against which hypothe-
ses can now be tested.
While intermediates along such a pathway have not
been demonstrated previously within cells, this could be a
consequence of their transient nature and the difficulties
involved in manipulating cellular systems. Further work
will be required to determine to what extent the mecha-
nism of cell-free HIV capsid assembly reflects biochemical
events that occur in vivo. Here we show that, under steady
state conditions, cells releasing immature HIV capsids con-
tain Pr55 complexes that correspond in approximate size
to complexes A, B, and C, the assembly intermediates ob-
served in the cell-free system. In addition, assembly-defec-
tive mutants arrested at specific complexes in the cell-free
system appear to be arrested in the form of similar sized
complexes when they are expressed in cells (Fig. 7). While
these data do not constitute proof that assembly interme-
diates exist in cells, they lend support to the idea that the
process of HIV capsid assembly in the cell-free system is
closely correlated to the capsid assembly process in cells. It
should be noted that in other biological systems, transient
intermediates that have been well documented in cell-free
reactions have yet to be identified in cells. For example, in
the case of targeting of nascent secretory proteins to the
endoplasmic reticulum, signal recognition particle–bound
nascent chains have been demonstrated biochemically only
in cell-free systems (Walter and Blobel, 1983), even though
genetic evidence confirms the importance of signal recog-
nition particles in vivo (Hann and Walter, 1991).
A Mechanistic View of HIV Capsid Assembly
In addition to allowing us to identify novel steps in HIV
capsid assembly, the cell-free system also allows us mecha-
Figure 8. A model for the assembly of immature HIV capsids. This model is based on the simplest interpretation of the data presented.
Newly synthesized Gag proteins are myristoylated cotranslationally. Nascent Gag polypeptides appear to chase into completed imma-
ture capsids by way of a series of Gag-containing complexes (complexes A, B, C, and D). Evidence presented in the text suggests that
complexes A, B, and C may constitute assembly intermediates. It is less clear whether complex D constitutes an assembly intermediate
or a side reaction. Both ATP and a subcellular fraction of eukaryotic cell extract are required for assembly to take place, while detergent
and apyrase are proposed to disrupt assembly at the indicated position. The points along the pathway at which various mutants of Gag
are arrested are indicated below the model. The Journal of Cell Biology, Volume 136, 1997 580
nistic insights into known aspects of capsid assembly. For
example, our data suggest that the reason that certain Gag
mutants fail to assemble is because they lack domains of
the Gag polypeptide that may be required, either directly
or indirectly, for progression from one assembly interme-
diate to the next along the proposed pathway for HIV
capsid assembly. Similarly, our results indicate that in the
absence of the myristate moiety or in the absence of intact
membranes, capsid assembly fails to progress beyond spe-
cific stages in the assembly process.
Altogether, we demonstrate that capsid assembly can be
disrupted at different points in the proposed assembly
pathway by five different means: (a) omitting MCoA dur-
ing the co-translational phase of the reaction, (b) depleting
ATP during the posttranslational phase, (c) treating with
detergent either at the start of translation or posttransla-
tionally, (d) removing the detergent-insensitive subcellular
component(s) from the eukaryotic cell lysate used for the
assembly reaction, and (e) programming the reaction with
assembly-defective Gag mutants. While details of the
mechanisms underlying these forms of blockade remain to
be determined by further analysis, these data reveal the
power of this approach for elucidating the biochemical
events that underlie capsid assembly.
Cell-free Assembly of Other Viral Capsids
Cell-free systems have been used in the past to assemble
simple viral particles whose formation is dependent only
on cytosolic components of host cells (Molla et al., 1991;
Lingappa et al., 1994; Sakalian et al., 1996). In the current
study we demonstrate that such systems can also be used
to reconstitute the assembly of much more complex viral
capsids, such as HIV capsids, that require co-translational
modifications as well as membrane targeting for their bio-
genesis. These data suggest that the cell-free system can be
used to examine capsid assembly mechanisms of many dif-
ferent types of viruses.
Previously, we used a cell-free system to study the mech-
anism of assembly of a Hepatitis B Virus (HBV), a com-
pletely unrelated virus (Lingappa et al., 1994). Unlike HIV
capsids, HBV capsids are formed free in the cytoplasm of
the host cell (for review see Ganem, 1991). We found that
these capsids assemble by way of an intermediate that is
associated with at least one host protein. When this inter-
mediate was isolated, manipulation of energy substrates
resulted in release of the completed capsid end product.
Thus, while cell-free HIV and HBV capsid assembly differ
greatly in many details and in their complexity, they share
some general mechanistic themes. Capsid formation in
both systems involves assembly intermediates, the use of
energy substrates, and association with host proteins.
Thus, we propose that viruses of very different types may
assemble their capsids via a step-wise pathway using host
cell machinery. Whether the same or different host ma-
chinery is recruited by various viruses remains to be deter-
mined.
Implications of the Cell-free System for Viral Assembly
To allow an analysis of the earliest events in capsid bio-
genesis, we designed this cell-free system to assemble the
simplest version of an HIV capsid, one that does not un-
dergo maturation and lacks HIV genomic RNA and HIV-
specific proteins (except for Gag). Now that the method
has been established, it should be possible to supplement
this system with such additional components in a manner
that will extend the reconstitution and allow the roles of
other components in capsid assembly to be determined.
For example, using a modified version of this system, it
should be possible to determine the requirements for en-
capsidation of viral RNA and viral specific enzymes. Note
that although no HIV-specific RNA besides the gag tran-
script is included in the cell-free reactions described in this
study, it is entirely possible that nonspecific RNA from the
cellular extract becomes incorporated into the capsids that
are made.
Recent studies demonstrating the highly dynamic nature
of HIV (Ho et al., 1995; Wei et al., 1995) indicate that the
only successful approach to combating this infection will
be simultaneous, multi-drug therapy. Antiretroviral agents
currently in use target only two aspects of the HIV life-
cycle, namely reverse transcription and protease-depen-
dent virion maturation. In order to develop novel targets
for future antiretroviral therapy, a mechanistic analysis of
other aspects of the HIV life cycle, such as capsid assem-
bly, must be aggressively pursued. The work presented
here establishes a means of carrying out such a biochemi-
cal analysis for assembly of the HIV capsid. Furthermore,
these data indicate the existence of novel steps in viral as-
sembly that appear to be amenable to blockade.
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